Peptide-Based Inhibitors Of The Phagocyte Nadph Oxidase by El-Benna, Jamel et al.
Peptide-Based Inhibitors Of The Phagocyte Nadph
Oxidase
Jamel El-Benna, Pham My-Chan Dang, Axel Pe´rianin
To cite this version:
Jamel El-Benna, Pham My-Chan Dang, Axel Pe´rianin. Peptide-Based Inhibitors Of The
Phagocyte Nadph Oxidase. Biochemical Pharmacology, Elsevier, 2010, 80 (6), pp.778.
<10.1016/j.bcp.2010.05.020>. <hal-00608935>
HAL Id: hal-00608935
https://hal.archives-ouvertes.fr/hal-00608935
Submitted on 16 Jul 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Accepted Manuscript
Title: Peptide-Based Inhibitors Of The Phagocyte Nadph
Oxidase
Authors: Jamel El-Benna, Pham My-Chan Dang, Axel
Pe´rianin
PII: S0006-2952(10)00359-X
DOI: doi:10.1016/j.bcp.2010.05.020
Reference: BCP 10575
To appear in: BCP
Received date: 30-3-2010
Revised date: 14-5-2010
Accepted date: 17-5-2010
Please cite this article as: El-Benna J, Dang PM-C, Pe´rianin A, Peptide-Based
Inhibitors Of The Phagocyte Nadph Oxidase, Biochemical Pharmacology (2008),
doi:10.1016/j.bcp.2010.05.020
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 46
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 1 
 
PEPTIDE-BASED INHIBITORS OF THE PHAGOCYTE NADPH OXIDASE 
 
  
 
Jamel El-Benna
1
, Pham My-Chan Dang
1
, and Axel Périanin
1,2
 
 
1
INSERM, U773, F-75018, France; Université Paris 7 Denis Diderot, Faculté de 
Medecine, site Bichat, Paris, F-75018, France. 
2
Institut Cochin, Université Paris 5 
Descartes, CNRS (UMR 8104), Paris, France, Inserm, U1016, Paris, France. 
 
Corresponding author: Dr Jamel El-Benna, INSERM U773, CRB3, Faculté de 
Medecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris France.  
Tel: 33 1 57 27 74 72; Fax: 33 1 57 27 74 61;  E-mail: jamel.elbenna@inserm.fr 
The authors have no competing interests to declare.  
Running title: NADPH oxidase-derived peptide inhibitors 
Abbreviations: DPI, di henylene iodonium; CGD, chronic granulomatous disease,  
fMLF, formyl-methionyl-leucyl-phenylalanine; MPO, Myeloperoxidase; phox, 
phagocyte oxidase; ROS, reactive oxygen species  
 
Page 2 of 46
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
ABSTRACT 
Phagocytes such as neutrophils, monocytes and macrophages play an essential role in 
host defenses against pathogens. To kill these pathogens, phagocytes produce and 
release large quantities of antimicrobial molecules such as reactive oxygen species 
(ROS), microbicidal peptides, and proteases. The enzyme responsible for ROS 
generation is called NADPH oxidase, or respiratory burst oxidase, and is composed of 
six proteins: gp91phox, p22phox, p47phox, p67phox, p40phox and Rac1/2. The vital 
importance of this enzyme in host defenses is illustrated by a genetic disorder called 
chronic granulomatous disease (CGD), in which the phagocyte NADPH oxidase is 
dysfunctional, leading to life-threatening recurrent bacterial and fungal infections. 
However, excessive NADPH oxidase activation and ROS overproduction can damage 
surrounding tissues and participate in exaggerated inflammatory processes. As ROS 
production is believed to be involved in several inflammatory diseases, specific 
phagocyte NADPH oxidase inhibitors might have therapeutic value. In this 
commentary, we summarize the structure and activation of the phagocyte NADPH 
oxidase, and describe pharmacological inhibitors of this enzyme, with particular 
emphasis on peptide-based inhibitors derived from gp91phox, p22phox and p47phox. 
 
Key words: Phagocytes, NADPH-oxidase, inhibitors, gp91phox/NOX2, p22phox, 
p47phox  
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1. Introduction 
Reactive oxygen species (ROS) produced by phagocytes are one of the most powerful 
host defenses against bacteria, yeasts and fungi [1, 2]. ROS produced by phagocytes 
include superoxide anion (O2
-.
), hydrogen peroxide (H2O2), hydroxyl radical (OH°) and 
hypochlorous acid (HOCl). These ROS are produced in large quantities when 
phagocytes are stimulated by pro-inflammatory agents or by particles such as bacteria. 
This process, known as the "oxidative burst" or “respiratory burst”, is characterized by 
a rapid, cyanide-insensitive increase in oxygen uptake and glucose consumption [1, 2]. 
Superoxide anion (O2 
-.
), the precursor of the other ROS, is first produced by an enzyme 
called NADPH oxidase, as follows [2, 3]:   
 
2 O2 + NADPH ---------> 2 O2 
-.
 + NADP
+
 + H
+ 
 
Once produced, O2 
-.
 is immediately transformed into H2O2 by spontaneous 
dismutation at acid pH in the phagosome, or through enzymatic dismutation by 
superoxide dismutase in the cytosol. Interaction between H2O2 and O2 
-.
can, through the 
Haber-Weiss rea tion in the presence of a transition metal (or the Fenton reaction in the 
presence of iron), give rise to the hydroxyl radical (OH°), one of the most powerful 
oxidants. H2O2 is also a substrate of myeloperoxidase, an enzyme stored in neutrophil 
azurophilic granules and released during neutrophil activation. Myeloperoxidase 
catalyses the transformation of H2O2, in the presence of a halogen (Cl
-
, Br
-
, I
-
), into 
highly toxic molecules such as hypochloric acid (HOCl
-
). Other reactions between OCl
-
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and H2O2 can lead to the formation of singlet oxygen (
1
O2). Most of the hypochlorous 
acid (OCl
-
) thus generated is converted into toxic chloramines. MPO can also use H2O2 
to oxidize tyrosines into tyrosyl radicals. HOCl-, chloramines and tyrosyl radicals, 
which are toxic species that serve to kill bacteria and other pathogens. The crucial role 
of phagocyte NADPH oxidase in host defenses against microbial pathogens is 
illustrated by a human genetic disorder called chronic granulomatous disease, which is 
associated with life-threatening recurrent bacterial and fungal infections [4]. However, 
excessive ROS production can damage healthy bystander tissues. ROS hyper-
production by neutrophils is believed to cause direct tissue insult in a broad range of 
inflammatory diseases, including rheumatoid arthritis, inflammatory bowel diseases, 
acute respiratory distress syndrome, sepsis, diabetic complications, cardiovascular 
disease, ischemic tissue injury and neurodegenerative diseases [5, 6]. Pharmacological 
NADPH oxidase inhibition might therefore be beneficial in patients with these 
disorders. Currently, there are no specific inhibitors of the phagocyte NADPH oxidase. 
Peptide-based inhibitors derived from specific subunits of the enzyme could provide a 
certain degree of specificity. In the first part of this manuscript, we review the principal 
features of NADPH oxidase in order to provide the information necessary to understand 
the action of the inhibitory peptides described in the second part.  
 
2. Components of the phagocyte NADPH oxidase 
The phagocyte NADPH oxidase is a multicomponent enzyme complex comprising six 
proteins, namely p22phox (phox: phagocyte oxidase), gp91phox, p47phox, p67phox, 
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p40phox and the small G-protein Rac1 or Rac2. In resting cells the NADPH oxidase is 
inactive because its components are distributed between the cytosol (p47phox, 
p67phox, p40phox and Rac1/2) and the plasma membrane and membranes of specific 
granules (p22phox and gp91phox/NOX2, which form the flavocytochrome b558). When 
cells are activated, the cytosolic components migrate to the membranes, where they 
associate with the membrane-bound components to assemble the catalytically active 
oxidase [7, 8]. 
Flavocytochrome b558 is the central membrane-bound component of NADPH oxidase 
[9]. It is composed of a 1:1 complex between a glycosylated 91-kDa protein subunit 
(gp91phox) of 570 amino acids (Figure1), and a non glycosylated 22-kDa subunit 
(p22phox) of 195 amino acids (Figure 2). Flavocytochrome b558 contains one FAD and 
two hemes and forms the NADPH oxidase electron transfer chain [9]. It serves as the 
central docking station for the cytosolic components, via numerous interaction sites [8]. 
P22phox is phosphorylated on threonine residues by a phosphatidic acid-activated 
kinase and PKC [10]. Gp91phox phosphorylation in human neutrophils
 
enhances its 
enzymatic activity and its binding to p47phox, p67phox and Rac1 [11]. 
P47phox is a cytosolic protein composed of 390 amino acids. Its COOH-terminal 
sequence is very basic and rich in serine and arginine [12, 13]. The amino acid 
sequence of p47phox also contains two src-homology 3 (SH3) domains, one phox 
homology (PX) domain, a proline-rich region and one autoinhibitory region (AIR) 
(Figure 3). P47phox binds to the flavocytochrome b558 during NADPH oxidase 
activation. P47phox is the subunit responsible for transporting the cytosolic complex 
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(p47phox-p67phox-p40phox) from the cytosol to the membrane during oxidase 
activation, and for organizing the different NADPH oxidase subunits. In intact cells, 
p47phox is extensively phosphorylated [13]. P67phox is composed of 526 amino acids, 
with two SH3 domains, four tetratricopeptide-rich regions and a proline-rich region
 
[7, 
12]. P67phox interacts with Rac1/2 and flavocytochrome b558 and can regulate its  
catalytic activity via a sequence called the activation domain [14]. P67phox is 
phosphorylated on serine and threonine residues by PKC-dependent and PKC-
independent pathways [15]. P40phox is a 339-amino-acid protein which was initially 
identified through its binding to p67phox. It contains one SH3 domain and one PX 
domain. P40phox is phosphorylated on serine 315 and threonine 154 by a PKC-
dependent mechanism [16]. Rac2 is the most abundant rac protein in human 
neutrophils, but rac1 (92% homologous with Rac2) is also present [12].  
 
3. Activation of the phagocyte NADPH oxidase 
3.1. Activation in intact neutrophils 
During neutrophil activation, 10-20% of cytosolic NADPH oxidase components 
migrate to the plasma membrane, where they bind to flavocytochrome b558 [7-9]. In 
intact cells, NADPH oxidase activation is accompanied by phosphorylation of p47phox, 
p67phox, p40phox, p22phox and gp91phox, along with several protein-protein 
interactions [10-14]. NADPH oxidase activation in phagocytes can be induced by a 
large number of particulate and soluble agents such as opsonized bacteria, opsonized 
zymosan, latex particles, formylated peptides such as formyl-Met-Leu-Phe (fMLF), and 
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also by pharmacological compounds such as calcium ionophores and PKC activators 
such as phorbol esters [17]. Other agents, such as pro-inflammatory cytokines (TNF, 
GM-CSF, IL-8, etc.) do not activate NADPH oxidase in neutrophils but instead induce 
a state of hyper-responsiveness to subsequent stimulation of NADPH oxidase and ROS 
production by agents such as fMLF, a process known as “priming” [17]. This 
phenomenon of “priming” or oxidative burst initiation is also observed in vivo, where it 
may play an important role in physiological regulation of bactericidal activity and also 
in host tissue injury in some inflammatory diseases.  
During neutrophil stimulation, p47phox is phosphorylated on multiple sites in its 
carboxy-terminal portion, including serines 303 to 379, which play a central role in 
NADPH oxidase activation and regulation [13]. In human neutrophils, among the 
various protein kinases involved in the regulation of NADPH oxidase activity, the PKC 
family appears to play a major role in the activation
 
[13,17]. Proinflammatory cytokines 
such as GM-CSF and TNF induce partial phosphorylation of p47phox on Ser345 [13, 
18]. Phosphorylation of p47phox on Ser345 represents a critical mechanism in the 
priming of ROS production by neutrophils at inflammatory sites. Thus, this site may be 
considered as a “priming site”. P47phox phosphorylation could potentially induce 
conformational changes
 
that initiate assembly of the active enzyme via interaction of 
the SH3 domain with the proline-rich region of p22phox
 
[12, 17]. In resting conditions 
the two SH3 domains of p47phox interact intramolecularly with the auto-inhibitory 
region in the non phosphorylated protein [7, 8]. This interaction switches to the 
p22phox-polyproline sequence when the enzyme is activated by phosphorylation [8]. 
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3.2. NADPH oxidase activation in cell-free systems  
NADPH oxidase can be activated in a cell-free system by mixing cytosol and plasma 
membranes isolated from resting neutrophils or macrophages in the presence of Mg
++
, 
GTP and an anionic amphiphile such as arachidonic acid or sodium dodecyl sulfate, 
which are believed to mimic phosphorylation by providing negative charges [19]. 
Active NADPH oxidase can also be reconstituted from recombinant or highly purified 
cytochrome b558, p47phox, p67phox and Rac proteins [20]. P40phox is not required 
for NADPH oxidase activation in a cell-free system, although it enhances NADPH 
oxidase activation in intact cells.  This cell-free system can also be activated by protein 
kinase C instead of anionic amphiphile agents
 
[21] and by physiological concentrations 
of phosphatidic acid [22]. This system has been used to examine the effect of various 
peptide inhibitors on NADPH oxidase activation. 
 
4. Homologues of phagocyte NADPH oxidases (NOXs) 
 Almost 30 years after the discovery of gp91phox, several homologues of this catalytic 
subunit have been described in human tissues such as lung, kidney and colon, and in 
various cell types (epithelial cells, endothelial cells, vascular smooth muscle cells)
 
[6, 
23]. These homologues have been cloned and grouped together under the acronym 
NOX, for NADPH oxidase (NOX1 to NOX5), or Duox, for dual oxidase (Duox1 and 
Duox2). NOX2 (gp91phox) is not restricted to phagocytes, as it is also expressed, albeit 
at lower levels, in endothelial cells, B and T lymphocytes, neurons, and other cell types 
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 9 
[23]. The main difference between phagocytic gp91phox/NOX2 and its homologues 
resides in the fact that ROS are produced in much smaller amounts by the new 
homologues. The other difference lies in their regulation, including the nature of the 
cytosolic subunits and their requirement. These new findings suggest that ROS might 
be involved in several cellular functions such as local tissue-specific bactericidal 
activity (in colon or lung) and intracellular signaling. The NOX1 and NOX3 
homologues are regulated by two NOX regulatory proteins called NOX organizer 1 
(NOXO1) and NOX activator 1 (NOXA1) [24, 25]. These are the respective 
homologues of p47phox and p67phox. Like p47phox, NOXO1 „organizes‟ the 
assembly of the fully active NOX1 enzyme complex. Indeed, it recruits NOXA1 to the 
membrane-bound NOX1 catalytic subunit through its interaction with p22phox and 
with membrane phosphoinositides [26, 27]. The small G protein Rac1 is also clearly 
involved in NOX1 activation, through its interaction with NOX activator 1. 
 
5. Phagocyte NADPH oxidase inhibition 
5.1. Chemical (non peptide) inhibitors 
  Many chemicals are known to inhibit ROS production by the phagocyte NADPH 
oxidase. Twenty years ago, Cross [28] listed numerous molecules with this effect, 
although few of them directly interact with or inhibit NADPH oxidase [29]. One of the 
first inhibitors of NADPH oxidase to be identified, and which is still widely used, is 
diphenylene iodonium (DPI), which inhibits electron transport by gp91phox/NOX2 
[30]. This molecule is a flavoprotein inhibitor and is therefore non specific for NOX2. 
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It inhibits not only other NOXs and DUOXs but also NO synthase and probably other 
flavoproteins [31]. However, in animal models, DPI inhibits ROS production and has 
an anti-arthritic effect [32]. It has been shown to reduce ethanol-induced liver 
inflammation in mice [33], and to inhibit pancreatic inflammation and fibrosis [34].  
Apocynin (4-hydroxy-3-methoxyacetophenone-substituted), a natural molecule 
structurally related to vanillin, inhibits the NADPH oxidase [35, 36]. It was reported to 
target p47phox, and its effect requires a peroxidase such as MPO [37]. It might be more 
specific for NOX2 but can  also inhibit NOX1 via NOXO1 in the presence of 
peroxidase. Apocynin also scavenges ROS, making it non specific for NOX2 [36, 38]. 
In vivo, apocynin was shown to attenuate collagen-induced arthritis in rats, to lower IL-
6 levels, and to reduce joint swelling [39] and zymosan-induced arthritis and 
inflammation in mice [40]. Apocynin also has other beneficial effects in vivo [41, 36]. 
Other molecules such as phenylarsine oxide (PAO), a sulfhydryl reagent for vicinal or 
proximal thiol groups, and 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), inhibit 
NADPH oxidase by preventing assembly of the complex [42, 43], but are also known 
for their inhibitory effects on other enzymes. PAO is a phosphotyrosine phosphatase 
inhibitor and AEBSF is a serine protease inhibitor. In rats, PAO inhibits ROS 
production and also attenuates LPS- and carrageenan-induced inflammation [44]. Many 
other small molecules have been shown to inhibit the phagocyte NADPH oxidase and 
other NOXs [45], but there are currently no specific chemical inhibitors for the 
phagocyte NADPH oxidase. Peptide inhibitors could be more specific than chemical 
inhibitors because they are derived from specific subunit sequences. In the following 
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part of the article we describe peptide inhibitors derived from each subunit described 
in the literature and discuss their specificity.  
 
5.2. Peptide inhibitors  
Gp91phox-derived inhibitory peptides. Peptides derived from gp91phox/NOX2 
have been used to inhibit NADPH oxidase. The first such peptides were the NOX2 
carboxy-terminal peptides RGVHFIF (amino acids 559-565) and 
SNSESGPRGVHFIFNKEN (amino acids 552-569), which inhibit phagocyte NADPH 
oxidase activation in cell-free systems (50% inhibitory concentration (IC50) = 32 µM) 
and, at higher concentrations, in electropermeabilized neutrophils [46-48]. Leusen and 
co-workers [49], showed that a point mutation of gp91phox (D500G) in X-linked 
chronic granulomatous disease patients resulted in an inactive NADPH oxidase and 
failure of p47phox/p67phox to translocate to membranes, and thereby identified a 
gp91phox/p47phox interaction domain encompassing D500 in gp91phox. The peptide 
sequence FAVHHDEEKDVITG, mimicking the 491-504 amino acids domain of 
gp91phox, inhibited superoxide generation in a cell-free system (IC50 = 10 µM) and 
also prevented membrane translocation of p47phox and p67phox. Using a random-
sequence peptide phage display library technique, DeLeo et al., identified several 
potential sites of interaction between p47phox and cytochrome b558 [50]. A peptide 
mimicking one gp91phox/p47phox interaction sequence, corresponding to amino acids 
77-93 (FLRGSSACCSTRVRRQL), had a potent inhibitory effect on human NADPH 
oxidase (IC50 = 1 µM). Another peptide, corresponding to amino acids 86-102, had a 
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potent inhibitory effect, with an EC50 of 2 µM [51]. Later, Rey et al., identified the 
corresponding sequence in mouse gp91phox and called it “gp91phox ds”, for gp91phox 
docking sequence [52]. They added a translocating TAT peptide (gp91ds-tat: 
RKKRRQRRR-CSTRIRRQL) to make it cell-permeable (see next section), and showed 
that it inhibited ROS production in neutrophils and mouse aorta, and also limited the 
increase in blood pressure elicited by an infusion of angiotensin II in mice [52]. 
Furthermore, Gp91ds-tat inhibited ROS production in aged rats [41], lowered 
proatherogenic molecule levels in rats [53], and attenuated neurovascular dysfunction in 
aged mice [54]. It is noteworthy that this gp91phox/NOX2 sequence is conserved in 
NOX1 and NOX4, meaning that it is not specific for the phagocyte NADPH 
oxidase/NOX2 but could act as a NOX1, NOX2 and NOX4 inhibitor. However, this 
peptide inhibits NOX2 in  cells, such as phagocytes, that express only this enzyme.  
Park et al., showed that peptides corresponding to gp91phox amino acid residues 27-46, 
87-100, 282-296, 304-321, 434-455 and 559-565 inhibited superoxide generation in a 
cell-free system with respective IC50 values of 34 µM, 40 µM, 30 µM, 35 µM, 25 µM 
and 53 µM [55]. A peptide corresponding to the predicted NADPH binding site in 
gp91phox also inhibited superoxide production in a cell-free system. The minimum 
sequence essential for this inhibitory effect consisted of amino acids 420-425 
(KSVWYK) and has an IC50 of 30 µM [56]. Interestingly, unlike other peptides that 
inhibit NADPH oxidase, this peptide was effective even when added after system 
activation. Kao et al., identified amino acids 419-430 (ILKSVWYKYCNN) as a Rac 
interaction site within NOX2, and generated a cell-permeant peptide by adding a TAT 
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sequence [57]. When used at 20 µM, this peptide inhibited ROS production in 
neutrophils stimulated by fMLF or PMA. This NOX2-Rac binding domain is conserved 
in NOX1 and NOX3 but not in NOX4, NOX5 or DUOXs, making it selective for 
NOX1, NOX2 and NOX3. Figure 4 represents the amino acid sequence of 
gp91phox/NOX2 and indicates the locations of the major inhibitory peptides. The 
regions covered by these peptides have more than 60% homology with NOX1, NOX2, 
NOX4 and NOX5, meaning that these peptides might also affect these homologues. 
The reason for this lack of specificity is that these peptides were identified before the 
discovery of NOX homologues. However, there are still several other NOX2 specific 
sequences which could be tested in order to identify specific inhibitory peptides.  
 
P22phox-derived inhibitory peptides. Nakanishi et al., first showed that the P22phox 
peptide AGGPPGGPQVNPIPVTDEVV (amino acids 175-194) inhibited superoxide 
production in a cell-free system, with an IC50 of 36 µM, and that it bound to p47phox 
[47]. A second peptide, corresponding to p22phox residues 82-95 
(PFTRNYYVRAVLHL), was then found to inhibit superoxide production with an IC50 
of 13 µM in a ell-free system consisting of solubilized neutrophil membranes and 
cytosol [58]. Using a “peptide walking” technique, Pick‟s group [59], identified 
peptides located in p22phox domains corresponding to amino acids 9-23, 31-45, 47-61, 
85-99 and 113-127, which inhibited NADPH oxidase activation in a cell-free system 
composed of macrophage membranes and recombinant proteins, with respective IC50 
values of 5.7, 3.0, 4.6, 2.0 and 3.0 µM. As p22phox is a subunit common to all NOXs, 
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p22phox-derived peptides are unlikely to specifically inhibit a particular type of 
NOX. Figure 5 represents the amino acid sequence of p22phox and the locations of the 
major inhibitory peptides.   
 
P47phox-derived inhibitory peptides. P47phox sequences have also been used to 
inhibit NADPH oxidase activation in a cell-free system or in electropermeabilized 
neutrophils. The p47phox peptide AYRRNSVRFL (amino acids 323-332) inhibits 
p47phox phosphorylation, p47phox translocation and NADPH oxidase activation in a 
cell-free system (IC50= 54 µM) [60, 61]. This peptide may compete either for p47phox 
phosphorylation, by acting as a pseudosubstrate for protein kinases, or for p47phox 
interaction with flavocytochrome b558 or p67phox [61]. A synthetic peptide comprising 
the amino acid sequence 323-332, corresponding to residues 314-331 
(RSRKRLSQDAYRRNSVRF), also inhibits p47phox phosphorylation, p47phox 
translocation and NADPH oxidase activation in human neutrophils [62]. DeLeo et al., 
identified sites of p47phox interaction with flavocytochrome b558 and used the 
corresponding peptides to inhibit NADPH oxidase [61]. In addition to peptide 323-332, 
they found that peptides corresponding to amino acids 315-332 and 334-347 inhibited 
superoxide production in a cell-free system and in electropermeabilized neutrophils, 
with respective IC50 values of 15 µM and 18 µM. Morozov et al., used the peptide-
walking technique to map p47phox functional domains involved in NADPH oxidase 
activation [63]. They showed that peptides corresponding to amino acids 5-19 (IC50= 
10.6 µM), 17-31 (IC50= 8.8 µM), 105-119 (IC50= 10.3 µM), 149-163 (IC50= 10.9 µM), 
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193-207 (IC50= 8.5 µM), 305-319 (IC50= 11.5 µM) and 325-339 (IC50= 3.4 µM) 
inhibited NADPH oxidase activation in a cell-free system. The most effective was the 
peptide corresponding to amino acids 325-339, which overlaps with the peptide 
described above by other investigators [60-62]. Three other inhibitory  peptides are 
located in the PX domain (amino acids 5-19, 17-31 and 105-119), two in the SH3 
domain (amino acids 149-163 and 193-207), and two in the carboxy-terminal 
phosphorylated domain (amino acids 305-319 and 325-339). P47phox is heavily 
phosphorylated in neutrophils, and this phosphorylation plays a major role in NADPH 
oxidase activation. Two peptides corresponding to p47phox phosphorylated sites 
(amino acids 301-320 and 314-335) inhibit NADPH oxidase activation (IC50= 7 and 6.7 
µM respectively) by inhibiting p47phox interaction with p22phox and its membrane 
translocation [64]. Among the p47phox phosphorylated sites, Ser345 plays a key role in 
NADPH oxidase hyperactivation or priming by pro-inflammatory cytokines such as 
TNF and GM-CSF, and also in inflammatory diseases such as rheumatoid arthritis 
[18] and intestinal inflammation [65]. Interestingly, a TAT-peptide sequence containing 
Ser345 (amino acids 334-347) was shown to inhibit NADPH oxidase hyper-activation 
in human neutrophils induced by TNF and GM-CSF, and hyperactivation of PMN 
from synovial fluid of RA patients, while preserving the physiological ability of 
bacterial N-formyl peptide to activate neutrophils [18]. Figure 6 represents the sequence 
of p47phox and the sites of the major inhibitory peptides. Since the PX and SH3 
domains are conserved between p47phox and NOXO1, peptides located in these 
domains are unlikely to be specific for NOX2. However, the AIR domain of p47phox 
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(amino acids 286-340) is missing in NOXO1, and peptides derived from this 
sequence could therefore represent good candidates for developing very specific 
inhibitors of the phagocyte NADPH oxidase, the activity of which requires the 
organizer subunit p47phox.  
 
Rac1-derived inhibitory peptides. The Rac1 peptide, corresponding to aa 178-188, 
inhibited NADPH oxidase activity in a cell-free system, with an IC50 of about 10 µM 
[66, 67]. Interestingly, the corresponding peptide sequence of Rac2 (aa 178-188) had no 
effect. The Rac1 sequence could thus be used to study the specific role of Rac1. 
Mapping of Rac1 functional domains by peptide walking has identified several 
inhibitory peptides (residues 73-81, 103-107, 123-133, 163-169 and 183-188) [68]. 
Like p22phox, Rac1 is a subunit common to all NOXs, making it unlikely that Rac1-
derived peptides would have a specific effect on a particular NOX.    
  
 
P67phox- and p40phox-derived inhibitory peptides. To our knowledge, no peptide 
sequences derived from p67phox or p40phox have yet been shown to inhibit the 
phagocyte NADPH oxidase. One possible reason is that p67phox was long considered 
to be an unstable protein with only a minor function in NADPH oxidase activation. 
However, in 1998, Han et al., showed that p67phox has an activation domain (amino 
acids 199-210) [14], and Diekman et al., showed that it binds Rac during activation by 
its N-terminal region (amino acids 1-199) [69]. These two p67phox sequences might be 
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used to develop new competitive inhibitory peptides. The reason for the lack of 
p40phox-derived peptides may be that p40phox is not required for NADPH oxidase 
activation in the cell-free system, making it more difficult to assess the effect of 
inhibitory peptides in intact cells.  
 
Inhibitory peptides not derived from NADPH oxidase components. A proline- and 
arginine- (PR) rich antibacterial peptide designated PR-39 (because it contains 19 
prolines and 10 arginines) inhibits NADPH oxidase activity (IC50= 1 µM) by targeting 
the interaction of the p47phox SH3 domain with p22phox [70]. This peptide has 
protective effects in experimental myocardial ischemia-reperfusion [71]. Because SH3 
domain/polyproline region interaction is involved in several protein/protein 
interactions, this peptide might inhibit processes other than NADPH oxidase activation.  
A cell-permeable dominant negative peptide (DN-Ets-1-TAT) derived from Ets-1, a 
transcriptional regulator of p47phox, was found to lower angiotensin II-induced 
p47phox expression and ROS production in vitro, and also to attenuate medial 
hypertrophy of the thoracic aorta in mice [72]. This strategy targets p47phox expression 
and not NADPH oxidase activation. Inhibition of NADPH oxidase expression is not a 
suitable strategy for neutrophils, because p47phox is already expressed in mature 
neutrophils; however, this peptide might alter p47phox expression in monocytes, 
macrophages or other cells which continuously express p47phox.   
Qin et al. showed that a tripeptide (GGF) contained in the dynorphin opioid peptide 
inhibited microglial NADPH oxidase at fentomolar concentrations and had 
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neuroprotective and anti-inflammatory effects [73]. The mechanism of action of this 
peptide is not known. 
 
6-Peptide delivery into living cells 
The main obstacle to the use of peptides to inhibit NADPH oxidase in intact living cells 
is their inability to cross the plasma membrane lipid bilayer. The use of cell-penetrating 
peptides (CPPs) or protein transduction domains (PTDs) is an attractive approach to 
this problem [74]. The most widely used CPPs are derived from the human 
immunodeficiency virus (HIV1) transactivator protein TAT, the Drosophila 
transcription factor antennapedia protein, and the herpes simplex virus (HSV) type 1 
protein VP22 [75]. Although the mechanism of peptide transduction is controversial, 
these peptides can deliver biologically active proteins, DNA, RNA, liposomes and 
nanoparticles across plasma membranes [74,75]. Several NADPH oxidase peptide 
inhibitors have already been coupled to TAT peptide and have been shown to inhibit 
ROS production in vitro and in vivo [18,52-54,57,72]. 
 
7-Conclusion and future perspectives 
NADPH oxidases/NOXs have essential roles in many physiological processes, 
including innate immunity, cell proliferation, gene expression, blood pressure 
regulation, antigen presentation and intracellular signaling. However, excessive ROS 
production by NADPH oxidases, and especially by the phagocyte NADPH oxidase 
NOX2, has been implicated in many inflammatory diseases, such as rheumatoid 
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arthritis, inflammatory bowel disease, acute respiratory distress syndrome, sepsis, 
diabetic complications, cardiovascular diseases, ischemic tissue injury and 
neurodegenerative diseases, in which ROS are believed to cause direct tissue insult. 
Thus, pharmacological targeting of the phagocyte NADPH oxidase/NOX2 might be 
beneficial in patients with these disorders. No specific chemical inhibitors for NOX2 
have so far been identified, and peptide-based inhibitors appear to be the most 
promising candidates, provided the target sequence is specific for a particular 
phagocyte NADPH oxidase component. The best targets for NADPH oxidase inhibitors 
are gp91phox/NOX2, p47phox and p67phox, because their expression is more specific 
for phagocytes. This tends to rule out the use of peptides derived from p22phox and 
Rac1/2, which are components common to all NOXs. 
The main problem with inhibitory peptides used to be their cell delivery, but this can 
now be achieved by coupling to cell-permeable peptides such as TAT or antennapedia 
peptide. Several cell-permeant peptide antagonists of NOX2 have already been shown 
to inhibit ROS production in vitro and in vivo, and have also served to identify new 
biological functions of the NADPH oxidase system. The other problem with peptides is 
their stability in live organisms. Interestingly, subcutaneous or intravenous infusion of 
NOX2-inhibitory peptides has been shown to attenuate vascular disorders in 
experimental animals. Oral administration is unlikely to provide efficient peptide 
delivery because of the hostile gastrointestinal invironment. Finally, candidate 
inhibitors should be specific for the phagocyte NADPH oxidase in order to avoid cross-
inhibition. The ideal NADPH oxidase inhibitor would prevent hyper-activity while 
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preserving the physiological functions of this key element in host defenses, as 
described above for the peptide derived from Ser345-p47phox sequence. Drugs that 
prevent NADPH oxidase priming and ROS over-production would be particularly 
valuable. 
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Figure legends 
 
Figure 1. Predicted structure of gp91phox/NOX2.  
The protein has a short N-terminal cytosolic sequence, 6 transmembrane helices, and 
one long C-terminal cytosolic tail containing the FAD binding site and one NADPH 
binding site. 
 
 
Figure 2. Predicted structure of p22phox.  
The protein has an N-terminal cytosolic sequence, 2 transmembrane helices, and one 
long C-terminal cytosolic tail containing a proline-rich region (PRR) which binds to 
p47phox SH3 domains. 
 
 
Figure 3. Predicted structure of p47phox.  
The protein has a phox homology (PX) domain, two src homology (SH3) domains, one 
auto-inhibitory region (AIR) and a proline-rich region (PRR). 
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Figure 4. Amino acid sequence of human gp91phox/NOX2 and sites of the major 
inhibitory peptides. Heavily hashed boxes represent predicted transmembrane alpha 
helices. Also indicated are putative FAD and NADPH binding sites. Bold and 
underlined sequences represent inhibitory peptides. 
  
 
Figure 5. Amino acid sequence of p22phox  and sites of the major inhibitory 
peptides. Heavily hashed boxes represent predicted transmembrane alpha helices. Also 
indicated is the proline-rich region (PRR). Bold and underlined sequences represent 
inhibitory peptides. 
 
 
Figure 6. Amino acid sequence of p47phox and sites of the major inhibitory 
peptides. Black boxes represent the phox homology domain (PX), white boxes the src 
homology domain 3 (SH3) domains, hashed boxes the auto-inhibitory region (AIR) and 
the proline-rich region (PRR). Bold and underlined sequences represent inhibitory 
peptides. 
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